Genenta Science S.P.A. (GNTA) — 6-K Filings

6-K Filings (18)

• Genenta Science Files 6-K Report — Mar 27, 2026 Risk: low
  Genenta Science S.p.A. filed a Form 6-K on March 27, 2026. This report is for a foreign issuer and includes various documents such as the 6-K form itself, an ex
• Genenta Science Files 6-K, Incorporates into F-3 — Nov 4, 2025 Risk: low
  On October 29, 2025, Genenta Science S.p.A. filed a Form 6-K, which is incorporated by reference into its Form F-3 registration statement (File No. 333-271901).
• Genenta Science Prices $10M Direct Offering — Oct 28, 2025 Risk: medium
  On October 26, 2025, Genenta Science S.p.A. announced a registered direct offering. The company intends to offer and sell shares of its common stock in the offe
• Genenta Science S.p.A. Files 6-K on Shareholder Meeting — Oct 27, 2025 Risk: low
  Genenta Science S.p.A. filed a Form 6-K on October 27, 2025, reporting on its Annual Ordinary Shareholders' Meeting held on April 29, 2025. This filing is incor
• Genenta Science Files 6-K Report — Oct 10, 2025 Risk: low
  Genenta Science S.p.A. filed a Form 6-K on October 10, 2025, reporting information for the period ending June 30, 2025. The filing is incorporated by reference
• Genenta Science CMO Resigns — Oct 3, 2025 Risk: medium
  On September 30, 2025, Carlo Russo, MD, notified Genenta Science S.p.A. of his resignation as Chief Medical Officer. His resignation is effective October 31, 20
• Genenta Science Announces Virtual Shareholder Meeting — Sep 10, 2025 Risk: low
  On September 10, 2025, Genenta Science S.p.A. announced its Ordinary and Extraordinary Shareholders' Meeting will be held virtually. The company, formerly known
• Genenta Science Amends Services Agreement with AGC Biologics — Aug 1, 2025 Risk: low
  On December 30, 2024, Genenta Science S.p.A. entered into the Second Amendment to its Development and Master Services Agreement with AGC Biologics S.p.A. This a
• Genenta Science Secures Up to €20M Financing — Mar 19, 2025 Risk: medium
  On March 19, 2025, Genenta Science S.p.A. announced a financing agreement for up to €20 million. This funding will be provided by ENEA Tech and Biomedical (ETB)
• Genenta Science Files 6-K on Agreement Amendment — Dec 30, 2024 Risk: low
  Genenta Science S.p.A. filed a Form 6-K on December 30, 2024, reporting a Second Amendment to its Development and Master Services Agreement. This filing is inco
• Genenta Science Amends ATM Sales Agreement — Dec 20, 2024 Risk: low
  On December 20, 2024, Genenta Science S.p.A. amended its At-the-Market (ATM) Sales Agreement. This amendment is incorporated by reference into the company's For
• Genenta Science Files 6-K with LOI Amendment Reference — Dec 13, 2024 Risk: low
  Genenta Science S.p.A. filed a Form 6-K on December 13, 2024, to incorporate by reference information into its Form F-3 registration statement (File No. 333-271
• Genenta Science S.p.A. Files 6-K, Mentions AGC Letter of Intent — Nov 14, 2024 Risk: medium
  Genenta Science S.p.A. filed a Form 6-K on November 14, 2024, incorporating information into its Form F-3 registration statement (File No. 333-271901). The fili
• Genenta Science Files 6-K for June 2024 Period — Oct 29, 2024 Risk: low
  Genenta Science S.p.A. filed a Form 6-K on October 29, 2024, reporting for the period ending June 30, 2024. The company, previously known as Genenta Science S.r
• Genenta Science S.p.A. Files 6-K Report — May 3, 2024 Risk: low
  On May 2, 2024, Genenta Science S.p.A. held its Ordinary Shareholders' Meeting in Milan, Italy. The company is a foreign private issuer filing a Form 6-K report
• Genenta Science S.p.A. Files Form 6-K — Apr 26, 2024 Risk: low
  On April 26, 2024, Genenta Science S.p.A. entered into an agreement that will be incorporated by reference into its Form F-3 registration statement (File No. 33
• Genenta CEO Proposes Acquisition — Apr 8, 2024 Risk: medium
  On April 4, 2024, Pierluigi Paracchi, CEO and a shareholder of Genenta Science S.p.A., submitted a proposal to the Board of Directors. This proposal concerns th
• Genenta Science Sets Stockholder Meeting Date — Apr 2, 2024 Risk: low
  Genenta Science S.p.A. announced on March 29, 2024, the date for its Ordinary and Extraordinary Meeting of Stockholders. The meeting will be held virtually, and

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX